OXON Real-World Evidence Alzheimer’s Research in 2024 Lancet Report
We are excited to announce that OXON’s Real-World Evidence (RWE) Alzheimer’s research has been prominently cited in the 2024 Lancet Commission on Dementia Report. This prestigious recognition underscores our commitment to advancing Alzheimer’s research and improving patient outcomes through evidence-based insights.
Significant Contribution
The Lancet Commission on Dementia is renowned for providing essential insights into dementia prevention, intervention, and care. Our inclusion in this esteemed report validates the impact and quality of our RWE Alzheimer’s research and highlights our role in shaping the future of Alzheimer’s treatment.
Expertise in Alzheimer’s Disease Research
At OXON, our dedication to Alzheimer’s disease research is demonstrated through our extensive expertise and innovative approaches. Our contributions are reflected in numerous publications across high-impact journals. Our key areas of focus include:
- Epidemiological Research: We conduct comprehensive studies to monitor disease prevalence, assess long-term risk factors, and analyze demographic impacts. This research helps track treatment effectiveness over time and identify emerging trends that influence public health strategies and interventions.
- Phase IV Clinical Trials: Our Phase IV studies are designed to evaluate the real-world effectiveness, safety, and long-term outcomes of treatments once they are on the market. We apply rigorous methodologies to ensure thorough data collection and analysis, providing insights into how treatments perform in diverse patient populations and everyday clinical settings.
- Real-World Evidence Studies: By utilizing real-world data, we provide actionable insights for drug evaluation and post-marketing surveillance. Our RWE studies bridge the gap between clinical trials and everyday practice, helping refine treatment protocols and improve patient outcomes by assessing therapy performance in real-world conditions.
- Market Access and Post-Market Surveillance: We support market access strategies through real-world data analysis to ensure that new therapies are effectively integrated into clinical practice. Our post-market surveillance services monitor ongoing safety and efficacy, offering the evidence needed for regulatory compliance and continued market support.
Leveraging Real-World Data
Our direct access to real-world dementia registry data enables us to support comprehensive RWE plans and studies. This data is vital for enhancing the clinical development, safety, and market access of Alzheimer’s drugs throughout their lifecycle. By integrating our expertise in epidemiology, clinical trials, and real-world evidence, we deliver insights that drive effective treatment strategies and regulatory decisions.
Discover More in Our Brochure
For an in-depth look at our research capabilities and services, we invite you to explore our Brochure. It provides detailed information on our approach to Alzheimer’s research, case studies, and how we can support your projects with our Real-World Evidence expertise.
Partner with OXON
Discover how OXON can support your research and development initiatives. Our proven track record in Real-World Evidence Alzheimer’s research and our innovative approach make us a valuable partner in advancing Alzheimer’s disease treatment. We invite you to collaborate with us to explore new opportunities and drive forward the progress in Alzheimer’s research.
Contact us to learn more about how we can work together and support your projects.